about
sameAs
Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signalsWhat is the best strategy for reducing deaths from heart disease?Intimal redox stress: accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. Atheroscleropathy.Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms.Altered interleukin-1 receptor antagonist and interleukin-18 mRNA expression in myocardial tissues of patients with dilatated cardiomyopathy.Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus.The utilization of nonthermal blue (405-425 nm) and near infrared (850-890 nm) light in aesthetic dermatology and surgery-a multicenter study.Childhood obesity: a life-long health riskInflammatory biomarkers in atherosclerosis: pentraxin 3 can become a novel marker of plaque vulnerability.Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications.Oxidized phosphatidylcholines: pattern recognition ligands for multiple pathways of the innate immune response.Lysophosphatidylcholine activates a novel PKD2-mediated signaling pathway that controls monocyte migrationImpact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetesNLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases.Tea and cardiovascular disease.Effects of chronic mental stress and atherogenic diet on the immune inflammatory environment in mouse aorta.Resolvins and protectins in inflammation resolution.The human myeloperoxidase gene is regulated by LXR and PPARalpha ligands.Traffic exposure in a population with high prevalence type 2 diabetes--do medications influence concentrations of C-reactive protein?Synthesis, enantioresolution, and activity profile of chiral 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones as potent N-formyl peptide receptor agonistsStatins as first-line therapy for acute coronary syndrome?Should C-reactive protein be a target of therapy?Statins in the first-line therapy of acute coronary syndrome - similar to aspirin?How can high-throughput screening deliver drugs to treat atherosclerosis?Advances in the role of microRNAs in lipid metabolism-related anti-atherosclerotic drug discovery.A review of the pharmacological effects of piceatannol on cardiovascular diseases.The melding of nanomedicine in thrombosis imaging and treatment: a review.Systematic evaluation on the effectiveness of conjugated linoleic acid in human health.LPS counter regulates RNA expression of extracellular proteases and their inhibitors in murine macrophages.Lysophosphatidic acid effects on atherosclerosis and thrombosis.Surface association of pregnancy-associated plasma protein-A accounts for its colocalization with activated macrophages.Cardiac Rehabilitation: Underrecognized/Underutilized.Effect of Angiotensin II Type 1 Receptor Antagonist, Losartan on Inflammatory Factor in Atherosclerotic Rabbits.Testin on Atherosclerosis in Rabbits.Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications.Transcription analysis of the responses of porcine heart to Erysipelothrix rhusiopathiae.Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model.Anti-phosphorylcholine-opsonized low-density lipoprotein promotes rapid production of proinflammatory cytokines by dendritic cells and natural killer cells.In the eye of the storm: T cell behavior in the inflammatory microenvironment.Monocyte chemoattractant protein-1 and CC-chemokine receptor-2 in severe hypercholesterolaemia.
P2860
Q24673096-1592E28D-E4B4-4FDA-BBE7-728A0F5A99C5Q24792163-E33FA4AF-E2C8-4CB3-82C8-B30485589E2EQ24796491-B6A8E499-9CFF-4538-9839-47E212F3B23CQ30319434-1B218F03-4268-44B8-97F0-A7F3FC05B528Q30319742-6E6C2740-9952-4BA4-A8BD-059EF15DA631Q31134484-C8425670-6715-4B9C-9040-DDD2DB3379B4Q33231709-843CBBE2-7B93-422B-9108-F40B74D7A514Q33567286-D464EA8A-BA47-45FE-AED7-CC720931EBB1Q33768947-48CEC158-80EA-4EF1-93D6-861166721D8DQ33901576-4384F8A9-FB96-45A4-B6C7-DD101B3861FFQ34188034-77EA03FC-5CAA-41F7-8FBD-7AA034E97D44Q34775050-1C6341FA-5B1D-4CE5-818B-8E39B473CC8CQ34955621-DC59AD7F-39CB-47B2-9A8D-158D7E531CE0Q35045146-82CEDD83-9CEC-4A4B-A61A-A2FFED6597C0Q35068802-7B1BBC33-C286-4959-B912-93C8748E5A78Q35318025-79B5BA29-A5F2-4DAD-BD5E-2F77D758749FQ35332873-7B6811F7-2DE9-4103-A88E-8DD07D7A114DQ35697554-508C52DE-DBF0-4332-9F2E-A924D94842D7Q36141065-0BD50CAB-0DE6-44E6-9616-1A3B957FD563Q36590244-523AED07-F4FA-4761-8297-BAE7BBA6BB1EQ36768488-3B323F50-E7BA-4B5E-9BCE-80E7FC11FAC2Q36783729-D12604EC-8965-4547-A2EB-27FBFF069F4CQ37276466-F2740ED4-CDA1-4DF4-846F-1FE7210604B7Q38028514-FADC7176-8665-4FFD-BAD8-A12A04D0C6A2Q38106172-1AF784AA-1CAD-46CC-8F84-CAD39A4D0E93Q38219561-9C52E7FA-A562-4297-80E3-ADCEB9663C34Q38776819-DDF907C2-99E6-4D1F-B5C3-4E762CEDAEF1Q38956410-BE9DA143-E968-4797-A7E5-5F1EA224C36CQ39359664-1E0BE7D2-52D2-4B9E-9D96-F26C40BB99E0Q39608397-03EBB6DA-88E6-4BC4-91ED-B1C71F4C72CFQ40220343-E459754D-9832-4727-9D73-B51F71F2FCEBQ40364939-18716A13-0D8A-472C-AB06-2FA24A62FDD2Q41724092-33BEB8B6-A143-4406-9A9B-3477602FD523Q41841666-2B2F59A1-C6C3-4943-BB75-401E5829B986Q41921823-AF4BEF51-8AEA-48D5-8389-CCFD33D10070Q41991307-B0E88FFD-F5E4-4467-A8D7-7D3B8D8E4C6AQ42063327-D41C6ADA-89B5-4B27-A8D4-02DA93344C4BQ43007723-664D61E6-6254-43ED-A452-2A6B6D37761CQ43087985-AFE7465B-76FC-4A6A-8906-839A500530DFQ44742540-38662F21-4B6A-4A8D-941A-D844D7E3A47B
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Atherosclerosis: the new view
@ast
Atherosclerosis: the new view
@en
Atherosclerosis: the new view
@nl
type
label
Atherosclerosis: the new view
@ast
Atherosclerosis: the new view
@en
Atherosclerosis: the new view
@nl
prefLabel
Atherosclerosis: the new view
@ast
Atherosclerosis: the new view
@en
Atherosclerosis: the new view
@nl
P1433
P1476
Atherosclerosis: the new view
@en
P356
10.1038/SCIENTIFICAMERICAN0502-46
P407
P50
P577
2002-05-01T00:00:00Z
P6179
1056528986